SCHEMBL194000

SCHEMBL194000

CCOc1cc(OCC)c2cc(C(=O)c3cccc4ccccc34)c(=O)oc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
RAB9A P51151 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 3/20 0.48
GLA P06280 2/20 0.48
GAA P10253 2/20 0.48
POLB P06746 2/20 0.47
CDC25B P30305 1/20 0.46
CNR1 P21554 4/20 0.46
CNR2 P34972 4/20 0.46
NPC1 O15118 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
CYP2C9 P11712 1/20 0.44
MAOB P27338 1/20 0.43
USP2 O75604 1/20 0.42
HSD17B10 Q99714 1/20 0.42
LMNA P02545 1/20 0.42
PPARG P37231 1/20 0.42
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6838345 0.88 ALDH1A1 (0.51) ALDH1A1RAB9ASMN1; SMN2KDM4EGLA
SCHEMBL52081 0.84 ALDH1A1 (0.68) ALDH1A1RAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL11096112 0.84 POLB (0.54) ALDH1A1RAB9ASMN1; SMN2KDM4EGAA
SCHEMBL51844 0.84 MEN1 (0.50) ALDH1A1RAB9AKDM4EGLAGAA
SCHEMBL11219985 0.79 RAB9A (0.49) ALDH1A1RAB9ASMN1; SMN2KDM4EGLA
SCHEMBL29253118 0.78 ALDH1A1 (0.62) ALDH1A1RAB9ASMN1; SMN2KDM4EGAA
SCHEMBL11564602 0.77 ALDH1A1 (0.53) ALDH1A1RAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL11563889 0.76 ALDH1A1 (0.52) ALDH1A1RAB9ASMN1; SMN2KDM4EGLA
SCHEMBL52567 0.76 ALDH1A1 (0.49) ALDH1A1RAB9ASMN1; SMN2KDM4EMAOB
SCHEMBL16538476 0.75 CDC25B (0.64) CDC25BCNR1CNR2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11382868-B2 Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same ICURE PHARMACEUTICAL INC. (KR) 2022-07-12 US claimed
CN-107652222-B Oxime ester photoinitiators 巴斯夫欧洲公司 2021-09-10 CN claimed
US-10919909-B2 Photoinitiated reactions LINTFIELD LIMITED (GB) 2021-02-16 US claimed
CN-105198793-B Oxime ester photoinitiators 巴斯夫欧洲公司 2019-08-13 CN claimed
US-20190211031-A1 PHOTOINITIATED REACTIONS LINTFIELD LIMITED (GB) 2019-07-11 US claimed
US-20190046463-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME ICURE PHARMACEUTICAL INC. (KR) 2019-02-14 US claimed
EP-3415141-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME Icure Pharmaceutical Inc. (KR) 2018-12-19 EP claimed
US-20250149336-A1 PHOTORESIST COMPOSITION AND METHOD OF MANUFACTURING INTEGRATED CIRCUIT DEVICE USING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-05-08 US disclosed
CN-114129544-B Ultraviolet curable hydrogel resin for transdermal administration, hydrogel, and cataplasm comprising same Icure药品株式会社 2025-03-21 CN disclosed
CN-119403840-A Photocurable composition, method for producing cured film, solid-state imaging element, image display device, and radical polymerization initiator 富士胶片株式会社 2025-02-07 CN disclosed
EP-4114825-B1 OXIME ESTER PHOTOINITIATORS BASF SE (DE) 2024-11-20 EP disclosed
WO-2024181097-A1 PHOTOCURABLE COMPOSITION, METHOD FOR PRODUCING CURED ARTICLE, FILM, OPTICAL ELEMENT, IMAGE SENSOR, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, AND RADICAL POLYMERIZATION INITIATOR 富士フイルム株式会社 2024-09-06 WO disclosed
CN-113316744-B Oxime ester photoinitiators with special aroyl chromophores 巴斯夫欧洲公司 2024-07-30 CN disclosed
WO-2003010602-A1 PHOTOSENSITIVE RESIN COMPOSITION CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-02-06 WO disclosed
WO-2002100903-A1 OXIME ESTER PHOTOINITIATORS HAVING A COMBINED STRUCTURE CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-12-19 WO disclosed
US-20020020832-A1 Photosensitive resin composition CIBA SPECIALTY CHEMICALS CORP. 2002-02-21 US disclosed
EP-1163553-A1 OXIME DERIVATIVES AND THE USE THEREOF AS PHOTOINITIATORS Ciba SC Holding AG (CH) 2001-12-19 EP disclosed
US-20010012596-A1 For resist applications; thermostability, storage stability CIBA SPECIALTY CHEMICALS CORP. 2001-08-09 US disclosed
CN-1305124-A Photosensitive resin composition CIBA SC HOLDING AG (CH) 2001-07-25 CN disclosed
WO-2000052530-A1 OXIME DERIVATIVES AND THE USE THEREOF AS PHOTOINITIATORS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919909-B2 Photoinitiated reactions KMO, DECR1, PPOX ALDH1A1 262/4885RAB9A 3269/4885SMN1; SMN2 4806/4885
US-20190211031-A1 PHOTOINITIATED REACTIONS DOHH, PAH, DBH ALDH1A1 179/4885RAB9A 4138/4885SMN1; SMN2 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.